Literature DB >> 24631070

Development of a Rift Valley fever virus viremia challenge model in sheep and goats.

Hana M Weingartl1, Myrna Miller2, Charles Nfon3, William C Wilson4.   

Abstract

Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, causes severe to fatal disease in newborn ruminants, as well as abortions in pregnant animals; both preventable by vaccination. Availability of a challenge model is a pre-requisite for vaccine efficacy trials. Several modes of inoculation with RVFV ZH501 were tested on goats and sheep. Differences in development of infectious viremia were observed between animals inoculated with RVFV produced in mosquito C6/36 cells compared to Vero E6 cell-produced inoculum. Only C6/36-RVFV inoculation led to development of viremia in all inoculated sheep and goats. The C6/36 cell-produced RVFV appeared to be more infectious with earlier onset of viremia, especially in sheep, and may also more closely represent a field situation. Goats were somewhat more resistant to the disease development with lower and shorter infectious virus viremia, and with only some animals developing transient increase in rectal temperature in contrast to sheep. In conclusion, a challenge protocol suitable for goat and sheep vaccine efficacy studies was developed using subcutaneous inoculation of 10(7)PFU per animal with RVFV ZH501 produced in C6/36 cells. Crown
Copyright © 2014. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Real-time RT-PCR; Rift Valley fever; Viremia; Virus isolation

Mesh:

Substances:

Year:  2014        PMID: 24631070     DOI: 10.1016/j.vaccine.2014.02.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  The tortoise or the hare? Impacts of within-host dynamics on transmission success of arthropod-borne viruses.

Authors:  Benjamin M Althouse; Kathryn A Hanley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

2.  Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Authors:  Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

3.  Evaluation of Fluorescence Microsphere Immunoassay for Detection of Antibodies to Rift Valley Fever Virus Nucleocapsid Protein and Glycoproteins.

Authors:  I K Ragan; A S Davis; D S McVey; J A Richt; R R Rowland; W C Wilson
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

4.  Experimental Infection of Domestic Piglets (Sus scrofa) with Rift Valley Fever Virus.

Authors:  Lorelei L Clarke; Daniel G Mead; Mark G Ruder; Deborah L Carter; Jennifer Bloodgood; Elizabeth Howerth
Journal:  Am J Trop Med Hyg       Date:  2021-10-25       Impact factor: 3.707

5.  Correlative Gene Expression to Protective Seroconversion in Rift Valley Fever Vaccinates.

Authors:  Richard C Laughlin; Kenneth L Drake; John C Morrill; L Garry Adams
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

Review 6.  Amending Koch's postulates for viral disease: When "growth in pure culture" leads to a loss of virulence.

Authors:  Joseph Prescott; Heinz Feldmann; David Safronetz
Journal:  Antiviral Res       Date:  2016-11-08       Impact factor: 5.970

7.  Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination.

Authors:  Gema Lorenzo; Elena López-Gil; Javier Ortego; Alejandro Brun
Journal:  Vet Res       Date:  2018-02-21       Impact factor: 3.683

Review 8.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

9.  Experimental Infection of Calves by Two Genetically-Distinct Strains of Rift Valley Fever Virus.

Authors:  William C Wilson; A Sally Davis; Natasha N Gaudreault; Bonto Faburay; Jessie D Trujillo; Vinay Shivanna; Sun Young Sunwoo; Aaron Balogh; Abaineh Endalew; Wenjun Ma; Barbara S Drolet; Mark G Ruder; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

10.  Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.

Authors:  George M Warimwe; Joseph Gesharisha; B Veronica Carr; Simeon Otieno; Kennedy Otingah; Danny Wright; Bryan Charleston; Edward Okoth; Lopez-Gil Elena; Gema Lorenzo; El-Behiry Ayman; Naif K Alharbi; Musaad A Al-dubaib; Alejandro Brun; Sarah C Gilbert; Vishvanath Nene; Adrian V S Hill
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.